{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:02Z","timestamp":1787071022581,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cervical cancer requires multimodality therapy, resulting in acute toxicities. Intensity-modulated radiation therapy (IMRT) is postulated to spare bone marrow (BM) and bowel to reduce acute hematological and gastrointestinal (GI) toxicities of chemoradiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This is a prospective randomized phase III study enrolling patients with Stage IB to IVA cervical carcinoma in two arms receiving either three-dimensional conformal radiotherapy (3DCRT) or IMRT from December 2017 to December 2019. The primary objective was to compare the hematologic toxicities (Grade 2 or more neutropenia as the primary factor) and the secondary objectives were to compare GI toxicities, and dosimetric analysis for volumes of BM, and bowel irradiated. SPSS version 20 was used for all statistical calculations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eighty patients with histopathologically confirmed cervical cancer were randomized to receive IMRT or 3DCRT (40 in each arm). The median age of the patients was 56.5 (36\u201367) and 59.5 (37\u201368) years, respectively, in IMRT and 3DCRT arms. The median dose of external radiation was 50 Gy in 25 fractions, and of brachytherapy was 24 Gy in 3 fractions in both the arms. The incidence of grade \u22652 neutropenia was 42.5% and 15% in the 3DCRT and IMRT arms, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). All patients received concurrent chemotherapy with cisplatin, with the median number of cycles being 5 (range 3\u20135) in both the arms. All five cycles of concurrent chemotherapy could be completed in 25 (62.5%) patients in the IMRT arm and 24 (60%) patients in the 3DCRT arm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>IMRT significantly reduces acute hematologic and GI toxicities compared with 3DCRT with a better dosimetry profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1242_20","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:37:21Z","timestamp":1668645441000},"page":"1490-1497","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A randomized study for dosimetric assessment and clinical impact of bone marrow sparing intensity-modulated radiation therapy versus 3-dimensional conformal radiation therapy on hematological and gastrointestinal toxicities in cervical cancer"],"prefix":"10.4103","volume":"18","author":[{"given":"Ankita Rungta","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra L","family":"Bhalavat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhay","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiba","family":"Moosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Markana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"Bauskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. V.","family":"Shincy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20241021","first-page":"125","article-title":"Cervical cancer: Prevention and treatment","volume":"14","author":"Denny","year":"2012","journal-title":"Discov Med"},{"key":"R2-6-20241021","first-page":"219","article-title":"The magnitude of cancer cervix in India","volume":"130","author":"Nandakumar","year":"2009","journal-title":"Indian J Med Res"},{"key":"R4-6-20241021","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"R5-6-20241021","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","article-title":"Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma","volume":"340","author":"Keys","year":"1999","journal-title":"N Engl J Med"},{"key":"R6-6-20241021","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0360-3016(94)90387-5","article-title":"Early and late radiotherapeutic morbidity in 442 consecutive patients with locally advanced carcinoma of the uterine cervix","volume":"29","author":"Pedersen","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-6-20241021","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.2004.07.197","article-title":"Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01","volume":"22","author":"Eifel","year":"2004","journal-title":"J Clin Oncol"},{"key":"R8-6-20241021","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix","volume":"18","author":"Peters","year":"2000","journal-title":"J Clin Oncol"},{"key":"R9-6-20241021","doi-asserted-by":"crossref","first-page":"503.e1","DOI":"10.1016\/j.ajog.2007.08.003","article-title":"Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: Follow-up of a Gynecologic Oncology Group trial","volume":"197","author":"Stehman","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"R10-6-20241021","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2017.01.033","article-title":"Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis","volume":"145","author":"Datta","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R11-6-20241021","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(01)05965-7","article-title":"Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis","volume":"358","author":"Green","year":"2001","journal-title":"Lancet"},{"key":"R13-6-20241021","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1002\/cncr.28849","article-title":"Complications of pelvic radiation in patients treated for gynecologic malignancies","volume":"120","author":"Viswanathan","year":"2014","journal-title":"Cancer"},{"key":"R14-6-20241021","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/1097-0142(197309)32:3<699::AID-CNCR2820320324>3.0.CO;2-V","article-title":"Bone marrow regeneration and extension after extended field irradiation in Hodgkin's disease","volume":"32","author":"Rubin","year":"1973","journal-title":"Cancer"},{"key":"R15-6-20241021","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.ijrobp.2006.03.018","article-title":"Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy","volume":"66","author":"Mell","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-6-20241021","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ijrobp.2009.11.062","article-title":"Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: Principal component analysis on high dimensional data","volume":"78","author":"Liang","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-6-20241021","first-page":"62","article-title":"Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: A national multi-center study","volume":"35","author":"Erpolat","year":"2014","journal-title":"Eur J Gynaecol Oncol"},{"key":"R18-6-20241021","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0360-3016(01)01664-9","article-title":"Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation","volume":"51","author":"Portelance","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R19-6-20241021","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4103\/0973-1482.126450","article-title":"Literature review with PGI guidelines for delineation of clinical target volume for intact carcinoma cervix","volume":"9","author":"Bansal","year":"2013","journal-title":"J Cancer Res Ther"},{"key":"R20-6-20241021","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/IGC.0000000000000292","article-title":"Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: Comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy","volume":"24","author":"Hui","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R21-6-20241021","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/0360-3016(95)00118-I","article-title":"Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix","volume":"32","author":"Eifel","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-6-20241021","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1148\/radiology.168.3.3043546","article-title":"Bone marrow imaging","volume":"168","author":"Vogler","year":"1988","journal-title":"Radiology"},{"key":"R23-6-20241021","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ics.2004.03.313","article-title":"Incorporation of magnetic resonance imaging into intensity modulated whole pelvic radiation therapy treatment planning to reduce the volume of pelvic bone marrow irradiated","volume":"1268","author":"Roeske","year":"2004","journal-title":"Int Congr Ser"},{"key":"R24-6-20241021","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11307-007-0112-5","article-title":"Magnetic resonance imaging based bone marrow segmentation for quantitative calculation of pure red marrow metabolism using 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a novel application with significant implications for combined structure-function approach","volume":"9","author":"Basu","year":"2007","journal-title":"Mol Imaging Biol"},{"key":"R25-6-20241021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.radonc.2005.06.017","article-title":"Incorporation of SPECT bone marrow imaging into intensity-modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies","volume":"77","author":"Roeske","year":"2005","journal-title":"Radiother Oncol"},{"key":"R26-6-20241021","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ijrobp.2008.04.046","article-title":"Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer","volume":"71","author":"Mell","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R27-6-20241021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijrobp.2013.01.017","article-title":"Hematologic toxicity in RTOG 0418: A phase 2 study of postoperative IMRT for gynecologic cancer","volume":"86","author":"Klopp","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R28-6-20241021","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijrobp.2016.11.027","article-title":"Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage Ib-Iva cervical cancer: An international multi-center phase Ii clinical trial (Intertecc-2)","volume":"97","author":"Mell","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R29-6-20241021","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0360-3016(01)02785-7","article-title":"Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies","volume":"52","author":"Mundt","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R30-6-20241021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13014-018-1126-7","article-title":"Intensity-modulated radiation therapy for definitive treatment of cervical cancer: A meta-analysis","volume":"13","author":"Lin","year":"2018","journal-title":"Radiat Oncol"},{"key":"R31-6-20241021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.brachy.2011.07.003","article-title":"American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles","volume":"11","author":"Viswanathan","year":"2012","journal-title":"Brachytherapy"},{"key":"R32-6-20241021","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.7314\/APJCP.2015.16.12.5075","article-title":"Impact of treatment time on chemoradiotherapy in locally advanced cervical carcinoma","volume":"16","author":"Pathy","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"R33-6-20241021","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2017.02.017","article-title":"Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer","volume":"123","author":"Li","year":"2017","journal-title":"Radiother Oncol"},{"key":"R34-6-20241021","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.ijrobp.2020.06.071","article-title":"A multi-atlas approach for active bone marrow sparing radiation therapy: Implementation in the NRG-GY006 Trial","volume":"108","author":"Yusufaly","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1242_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:28Z","timestamp":1787067628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1242_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1242_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}